ALKS — Alkermes plc

Summary of Alkermes (ALKS) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $392.9 million, reflecting strong growth.
• Net Sales from Proprietary Products: Increased 38% year-over-year to $338.1 million.
• Net Sales Breakdown:
  • VIVITROL: $112.4 million.
  • ARISTADA: $93.8 million.
  • LYBALVI: $92.4 million (32% year-over-year growth).
  • LUMRYZ: $72 million in net revenue for the quarter (including $39.5 million in the first 6 weeks post-acquisition).
• GAAP Net Loss: $66.5 million.
• Adjusted EBITDA: Positive $80.3 million, exceeding prior expectations.
• Cash Position: Approximately $538 million in cash and investments post-acquisition of Avadel Pharmaceuticals.

2. Strategic Updates and Business Highlights

• Acquisition of Avadel Pharmaceuticals: Completed in mid-February 2026, enhancing Alkermes' portfolio with LUMRYZ, a sodium oxybate treatment for narcolepsy.
• Expansion into Sleep Medicine: The acquisition allows for early engagement with sleep specialists, positioning Alkermes for future launches, particularly for Alixorexton.
• Orexin Programs: Strong focus on expanding the orexin therapeutic class beyond sleep disorders, with new clinical studies planned for ADHD and fatigue associated with multiple sclerosis and Parkinson's disease.
• Clinical Development: Progress on the Alixorexton Phase III Brilliance studies for narcolepsy, with strong investigator interest and enrollment underway.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of more than $1.7 billion and adjusted EBITDA exceeding $370 million.
• LUMRYZ Sales Forecast: Anticipated net sales in the range of $350 million to $370 million for the year.
• VIVITROL Sales Forecast: Expected net sales between $460 million and $480 million.
• ARISTADA Sales Forecast: Expected net sales between $365 million and $385 million.
• LYBALVI Sales Forecast: Expected net sales between $380 million and $400 million.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The entry of Eli Lilly into the orexin therapeutic space raises competitive concerns, although Alkermes believes its data and pipeline position it favorably.
• Potential Price Pressure: Concerns about pricing dynamics for LUMRYZ as non-AG generic sodium oxybate products gain market traction, though current demand remains strong.
• Debt Load: Following the acquisition, Alkermes took on significant debt ($1.525 billion in term loans), which could impact financial flexibility.

5. Notable Q&A Insights

• Orexin Programs: There is confidence in the potential of ALKS 7290 for ADHD, with preclinical data suggesting efficacy comparable to stimulants. The company plans to initiate Phase II studies this summer.
• LUMRYZ in Idiopathic Hypersomnia (IH): The company anticipates a significant market opportunity, with a focus on both new patients and switches from existing treatments.
• Patient Enrollment: The company is optimistic about enrollment rates for clinical trials, particularly for Alixorexton, due to strong interest from investigators and the existing data set.
• Market Dynamics: The management emphasized that VIVITROL's unique manufacturing and commercial requirements may mitigate the impact of generic competition.

Overall, Alkermes reported a strong start to 2026, driven by solid sales growth and strategic acquisitions, while navigating potential competitive and market challenges.